REFERENCES
- Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette—Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116: 180–183.
- Shang PF, Kwong J, Wang ZP, et al. Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and Ti bladder cancer (Review). Cochrane Database Syst Rev 2011; (5): CD006885.
- Lamm DL. Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer. Clin Infect Dis 2000; 31 Suppl 3:586–90.
- Koya MP, Simon MA, Soloway MS. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol 2006; 175(6): 2004–2010.
- Fradet V, Gaudreau C, Perrotte P, et al. Management of hepatic granulomatous tuberculosis complicating intravesical BCG for superficial bladder cancer. Can Urol Assoc J 2007; 1(3): 269–272.
- Outryve SMV, Francque SM, Gentens PA, et al. Bacillus Calmette — Guerin-induced granulomatous hepatitis in a patient with a superficial bladder carcinoma. Eur J Gastroenterol Hepatol 2004; 16(10): 1027–1032.
- Gonzalez OY, Musher DM, Brar I, et al. Spectrum of bacille Calmette-Guérin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis 2003; 36(2): 140–148.
- Rischmann P, Desgrandchamps F, Malavaud B, et al. BCG intravesical instillations: recommendations for side-effects management. Eur Urol 2000; 37 Suppl 1:33–36.
- Watts MR, Taylor PC, Sintchenko V, et al. Implications of isoniazid resistance in Mycobacterium bovis Bacillus Calmette-Guérin used for immunotherapy in blad-der cancer. Clin Infect Dis 2011; 52(1): 86–88.